NCT06377059 Early Detection of Complications During Immunotherapy for Haematological Malignancy
| NCT ID | NCT06377059 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Hematologic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-12-02 |
| Primary Completion | 2026-12-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Aims * To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patients diagnosed with haematologic malignant disease (e.g. malignant lymphoma) * Patients scheduled for treatment with CART or BsAbs Exclusion Criteria: * Patient is pregnant * Patient has a pacemaker * Patient is allergic to one or more of the materials that the equipment consists of * Investigator deems patient not able to comply with participation in the study
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.